Precision BioSciences (DTIL)

• Market cap: $35M
• 1 day: -8.06%
• 5 days: -21.11%
• 1 month: 1.33%
• 3 months: -48.30%
• 6 months: -54.22%
• Year to date: -2.77%
• 1 year: -59.14%
• 5 years: -98.57%
• 10 years: -99.13%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Employees: 108

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

11% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 9

9% more funds holding

Funds holding: 47 [Q2] → 51 (+4) [Q3]

0.2% more ownership

Funds ownership: 45.77% [Q2] → 45.97% (+0.2%) [Q3]

3% less capital invested

Capital invested by funds: $30.9M [Q2] → $29.8M (-$1.07M) [Q3]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $34 646% upside
• Avg. target: $47 931% upside
• High target: $60 1,216% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Patrick Trucchio 29% 1-year accuracy 45 / 156 met price target	1,216% upside $60	Buy Reiterated	10 Jan 2025
BMO Capital Kostas Biliouris 22% 1-year accuracy 5 / 23 met price target	646% upside $34	Outperform Upgraded	10 Jan 2025